Volume 101, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



A 2-visit multiple-site intradermal (ID) vaccine protocol would be the most economical, immunogenic, and practicable regimen for postexposure rabies prophylaxis (PEP) in clinics seeing few patients a month. This regimen with an additional day 28 dose is now recommended by the WHO. The difficulties surrounding ID rabies vaccination have hindered progress in provision of prophylaxis, especially in rural Asia and Africa. Although the latest WHO recommendations include 1-week ID postexposure vaccine regimens, these are unlikely to prove economical where rabies vaccination is presently unavailable. The new protocol uses a whole vial of vaccine divided between 4-sites ID on the first day and half a vial at 2-sites ID on day 7. Gavi has recently approved support for rabies PEP. This 2-visit 4-site ID regimen, with or without a day 28 dose, should be considered for implementation in this remarkable new initiative.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Suraweera W, Morris SK, Kumar R, Warrell DA, Warrell MJ, Jha P; Million Death Study Collaborators, 2012. Deaths from symptomatically identifiable furious rabies in India: a nationally representative mortality survey. PLoS Negl Trop Dis 6: e1847.
    [Google Scholar]
  2. Warrell MJ, 2019. Rabies post-exposure vaccination in 2 visits within a week: a 4-site intradermal regimen. Vaccine 37: 11311136.
    [Google Scholar]
  3. World Health Organization, 2018. World Health Organization Expert Consultation on Rabies. Second Report. Technical Report Series 1012. Geneva, Switzerland: WHO. Available at: http://apps.who.int/iris/bitstream/handle/10665/272364/9789241210218-eng.pdf?ua=1. Accessed March 29, 2019.
    [Google Scholar]
  4. SAGE Working Group on Rabies Vaccines and Immunoglobulins and the World Health Organization Secretariat, 2017. Background Paper: Proposed Revision of the Policy on Rabies Vaccines and Rabies Immunoglobulins. Available at: http://www.who.int/immunization/sage/meetings/2017/october/1_Background_paper_WG_RABIES_final.pdf. Accessed March 29, 2019.
    [Google Scholar]
  5. Warrell MJ et al., 1985. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1: 10591062.
    [Google Scholar]
  6. World Health Organization, 1997. WHO Recommendations on Rabies Post-Exposure Treatment and the Correct Technique of Intradermal Immunization Against Rabies. WHO/EMC/ZOO.96.6. Available at: http://www.who.int/rabies/en/WHO_recommendation_post_exp_treatment.pdf. Accessed March 29, 2019.
    [Google Scholar]
  7. Madhusudana SN, Anand NP, Shamsundar R, 2001. Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies. Natl Med J India 14: 145147.
    [Google Scholar]
  8. Madhusudana SN, Saha SM, Sood M, Saxena SN, 1988. Multisite intradermal vaccination using tissue culture vaccine as an economical prophylactic regimen against rabies. Indian J Med Res 87: 14.
    [Google Scholar]
  9. World Health Organization, 2005. WHO Expert Consultation on Rabies. Tech Rep Ser 931. Available at: http://apps.who.int/iris/bitstream/10665/43262/1/WHO_TRS_931_eng.pdf?ua=1&ua=1. Accessed May 20, 2019.
    [Google Scholar]
  10. Warrell MJ et al., 2008. A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods. PLoS Negl Trop Dis 2: e224.
    [Google Scholar]
  11. Warrell MJ, 2018. Developments in human rabies prophylaxis. Rev Sci Tech 37: 629647.
    [Google Scholar]
  12. Ambrozaitis A, Laiskonis A, Balciuniene L, Banzhoff A, Malerczyk C, 2006. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. Vaccine 24: 41164121.
    [Google Scholar]

Data & Media loading...

  • Received : 02 Apr 2019
  • Accepted : 24 Jun 2019
  • Published online : 05 Aug 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error